Mandate

Vinge has advised Pandox in connection with a directed share issue of approximately SEK 3 billion

November 06, 2019 Capital Markets and Public M&A

Vinge has advised the hotel property owner Pandox in connection with a directed share issue of 16,350,000 class B shares, whereby Pandox will receive approximately SEK 3 billion in issue proceeds.

The subscription price was determined to SEK 186.50 per share through an accelerated book building process. The share issue was directed to approximately 130 Swedish and international institutional investors. The purpose of the share issue is increase the financial flexibility for additional acquisitions and further strengthen the company’s competitive position in the international hotel property market.

Vinge’s team consisted of Jesper Schönbeck, Nils Fredrik Dehlin and Hampus Olsson.

Related

Vinge has advised Vimian Group AB in connection with its uplisting to Nasdaq Stockholm

Vinge has advised Vimian Group AB (publ) in connection with its list change from Nasdaq First North Growth Market to Nasdaq Stockholm’s main market, Large cap. The prospectus was published on 21 March 2025 and the trading on Nasdaq Stockholm commenced on 28 March 2025.
March 28, 2025

Vinge advises Tribune Therapeutics in conjunction with financing round

Vinge advises Tribune Therapeutics, a Swedish biotechnology company focused on developing therapies for fibrotic diseases, in raising 23 MEUR. The financing round includes the previous investors HealthCap, Novo Holding and Innovestor, in addition to the new investors LifeArc Ventures, Industrifonden and Investinor.
March 26, 2025

Vinge advises Dignitana on the public offer from Paxman

Paxman AB (publ) has announced a public offer to the shareholders of Dignitana AB. The total value of the offer is approximately SEK 153 million.
March 24, 2025